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Pre-intensive care unit (ICU) induction of targeted temperature management (TTM) with cold 72 
intravenous (i.v.) fluids does not appear to improve outcomes after in out-of-hospital cardiac arrest 73 
(OHCA). We hypothesized that this may be due to ineffective cooling and side effects.  74 
Methods 75 
A post hoc analysis of a sub-group of patients (n=352) in the TTH48 trial (NCT01689077) who 76 
received or did not receive pre-ICU cooling using cold i.v. fluids. Data collection included patient 77 
characteristics, cardiac arrest factors, cooling methods, side effects and continuous core 78 
temperature measurements. The primary endpoint was the time to target temperature (TTT, < 79 
34°C), and the secondary endpoints included the incidence of circulatory side effects, abnormal 80 
electrolyte levels and hypoxia within the first 24 h of ICU care. A difference of 1 h in the TTT was 81 
determined as clinically significant a priori.  82 
Results  83 
Of 352 patients included in the present analysis, 110 received pre-ICU cold fluids. The median time 84 
to the return of spontaneous circulation (ROSC) and TTT in the pre-ICU cold fluids group was longer 85 
than that of the group that did not receive pre-ICU cold fluids (318 vs. 281 min, p < 0.01). In a linear 86 
regression model including the treatment centre, body mass index (BMI), chronic heart failure, 87 
diabetes mellitus and time to ROSC, the use of pre-ICU cold i.v. fluids was not associated with a 88 
shorter time to the target temperature (standardized beta coefficient: 0.06, 95% CI for B -49 and 16, 89 
p = 0.32). According to the receipt or not of pre-ICU cold i.v. fluids, there was no difference in the 90 
proportion of patients with hypoxia on ICU admission (1.8% vs. 3.3%, p = 0.43) or the proportion of 91 
patients with electrolyte abnormalities (hyponatremia: 1.8% vs. 2.9% p = 0.54; hypokalaemia: 1.8% 92 




The initiation of TTM with cold i.v. fluids before ICU arrival did not decrease the TTT. We detected 95 
no significant between-group difference in mortality or the incidence of side effects according to 96 
the administration or not of pre-ICU cold i.v fluids. 97 
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Targeted temperature management (TTM) is commonly utilised in the treatment of out-of- hospital 119 
cardiac arrest (OHCA) patients.1,2 The optimal mode and timing of induction are unclear.3 Although 120 
several cooling methods are used in the intensive care unit (ICU), pre-ICU cooling is generally 121 
performed using cold intravenous (i.v.) fluids, given the simplicity of the method. According to some 122 
small studies, potential benefits associated with this pre-ICU cold i.v. fluids included a shorter time 123 
to the target temperature (TTT).4-6 However, a previous study reported that the administration of 124 
cold i.v. fluids prior to the time to return of spontaneous circulation (ROSC) led to increased side 125 
effects.7 Some recent resuscitation guidelines have advised against the use of pre-ICU cold i.v. 126 
fluids.8 In a large randomised controlled trial (RCT) on the use of pre-hospital cold fluids for TTM (N 127 
= 1,000), Kim et al. found no clear survival benefit and an elevated risk of pulmonary oedema.4 128 
Intuitively, rapid cooling after cardiac arrest should improve outcomes. However, it is not clear how 129 
possible benefits and disadvantages of rapid cooling interact, resulting in mixed evidence on the 130 
value of pre-ICU cold i.v. fluids.3,4,9-16 We hypothesized that the lack of a clear benefit may be due 131 
to ineffective cooling or side effects of the cold pre-ICU i.v. fluids. If these side effects were better 132 
understood, it might be possible to tailor treatments and ultimately use cold i.v. fluids as a cheap, 133 
simple and applicable method to induce hypothermia before ICU admission.  134 
In the present study, we aimed to determine the effects of pre-ICU cooling using cold i.v. fluids on 135 
the TTT and incidence of side effects in a sub-group of patients treated with either standard or 136 
prolonged TTM at 33°C included in the TTH48 trial.17 137 
Methods 138 
Study population and setting 139 
We performed a post hoc analysis of a sub-group of patients in the TTH48 trial (NCT01689077) who 140 
received or did not receive pre-ICU cooling using cold i.v. fluids. The original study compared TTM 141 
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at 33°C for 48 h versus 24 h in the ICU after OHCA. The protocol and statistical analysis of the TTH48 142 
trial have been published previously.17,18 The original study included 355 unconscious OHCA patients 143 
in 10 European ICUs who were randomized to TTM at 33°C for either 48 or 24 h. The inclusion criteria 144 
were a Glasgow Coma Scale score of less than 8, aged between 18 and 80 y and ROSC sustainment 145 
for more than 20 min prior to randomization. The exclusion criteria included terminal disease or a 146 
do-not-resuscitate order, systolic blood pressure less than 80 mmHg, non-cardiac cause of cardiac 147 
arrest, time to ROSC longer than 60 min, in-hospital cardiac arrest, severe coagulopathy, initial 148 
rhythm asystole in an unwitnessed OHCA, time from cardiac arrest to initiation of cooling of > 240 149 
min, neurological disease with cognitive impairment, persistent cardiogenic shock, an acute stroke 150 
or intracerebral bleeding and acute coronary bypass surgery.  151 
On the first hospital day, the patients were screened in the ICU and could be included until 23 h 152 
from reaching the target temperature. In some patients, TTM was initiated before ICU arrival using 153 
cold fluids, and the amount and type of fluid were recorded in the case report form (CRF). There 154 
was no protocol for pre-ICU cold i.v. fluids administration (i.e. fluids were given as deemed 155 
appropriate by the treating clinician). Core bladder, rectum or oesophagus temperatures were 156 
measured using intravascular probes. Target temperature was maintained using either invasive or 157 
surface cooling devices. After TTM was maintained at 33°C for the duration mandated by 158 
randomization, rewarming was started at a rate of 0.5°C/h until a temperature of 37°C was reached. 159 
In cases of severe adverse events, such as a recurring cardiac arrest, the treating clinician could 160 
select to rewarm patients early at a rate of 0.5°C/h to 36°C.  161 
Endpoints 162 
The primary endpoint was the time from ROSC to reaching a target temperature of < 34°C. A 163 
reduction of at least 1 h in the TTT was considered clinically significant. We created composite 164 
endpoints to compare successful cooling and the global efficacy of cooling. Successful cooling was 165 
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defined as the time from ROSC to reaching the target temperature of less than 294 min (median). 166 
Globally effective cooling was defined as successful cooling without any of following: severe 167 
arrhythmia, considered pulseless ventricular tachycardia/ventricular fibrillation or unstable 168 
haemodynamics, despite treatment; a severe circulatory adverse event, defined as MAP of < 60 169 
mmHg, despite comprehensive treatment; or hypoxia, defined as paO2 of < 8 kPa. Other outcome 170 
endpoints included any occurrence of abnormal electrolyte levels or hypoxia during the first 24 h of 171 
ICU care, adverse events during the ICU stay and survival and neurological outcomes 6mo after 172 
hospital discharge. Survival status after 24, 48 and 72 h was recorded, in addition to seizures, 173 
circulatory hypotension, arrhythmias, gastrointestinal adverse events, renal replacement, 174 
pneumonia, infections, sepsis, bleeding and transfusions. We used the same definitions for adverse 175 
effects and a favourable neurological outcome (CPC1 or 2) as those applied in the original TTH48 176 
study.17 In terms of electrolyte abnormalities, hypernatremia hyponatremia, hypokalaemia and 177 
hypochloraemia were classified as Na+ > 145 mmol/L, Na+ < 130 mmol/L, K+ < 3.0 mmol/L and Cl- > 178 
109 mmol/L, respectively. Any respiratory adverse event was considered hypoxia. 179 
Statistical methods 180 
The study population was divided into two groups according to whether pre-ICU cold i.v. fluids were 181 
administered. Categorical data are presented as numbers of patients and percentages. Continuous 182 
parameters were assessed for normality and presented either as means (standard deviation [SD]) 183 
or medians (interquartile range [IQR]). Categorical parameters were compared using a chi-square 184 
test. Continuous variables were compared using the Student’s T-test or Mann–Whitney U test.  185 
We performed a multivariate linear regression to determine the effects of pre-ICU cold i.v. fluid 186 
cooling on the time from ROSC to reaching the target temperature. We analysed baseline factors 187 
associated with successful cooling and performed univariate linear regression analysis on ROSC to 188 
target temperature time for baseline factors associated with successful cooling with p < 0.20. In the 189 
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multivariate linear regression analysis, factors with a p value of < 0.05 in the univariate analysis were 190 
included. Factors included in the multivariate linear regression model were the use of pre-ICU cold 191 
i.v. fluids, ROSC delay, treatment centre, previous heart failure, diabetes mellitus and body mass 192 
index (BMI). Weight was excluded to avoid collinearity with BMI. The mean (SD) hourly 193 
temperatures of each patient were calculated during the first 24 h and compared using a mixed 194 
linear model with compound symmetry that included the interaction between cold fluid use with 195 
time. In cases where data on mean hourly temperatures of a patient were missing, the patient was 196 
excluded from the mean hour temperature analysis. All other patient-related measurements were 197 
included in the model. Mortality and time to death were visualized using Kaplan–Meier curves, and 198 
the mortality between groups was compared using a log rank test. A p value of < 0.05 was 199 
considered significant. All analyses were conducted using IBM SPSS Statistics for Windows, Version 200 
25.0. (IBM Corporation, Armonk, NY, USA) and Microsoft Excel 2016 (Microsoft Corporation, 201 
Redmond, Washington, USA) 202 
Results 203 
Included patients 204 
Of the 355 patients included in the original trial, 352 were included in the present analysis, of which 205 
110 received pre-ICU cold i.v. fluids. Exact cooling times were available for 345 patients, and these 206 
data were included in the TTT analysis. The pre-ICU cold fluids administered included 500–3,000 ml 207 
(median 1000ml IQR 1000-2000 ml) of 4°C saline, Ringer’s solution or another crystalloid solution, 208 
such as salt solutions (e.g. saline) with small molecules.  209 
Baseline characteristics 210 
The baseline and resuscitation characteristics of the patients who received cold fluids and those 211 
who did not were compared (Table 1). There were more patients with chronic heart failure (NYHA 212 
class 4) in the group given pre-ICU cold fluids (11.8% vs. 2.1%, p < 0.001), as shown in Table 1. There 213 
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were no other significant between-group differences in the baseline characteristics of the patients, 214 
including cardiac arrest- or resuscitation-related factors (Table 1). 215 
TTM-related factors 216 
Table 2 provides information on factors relating to the induction and maintenance of TTM. The 217 
mean (347 min vs. 268 min, p = 0.01) and median (318 min vs. 281 min, p < 0.01) times from ROSC 218 
to reaching the target temperature increased significantly in the group given pre-ICU cold i.v. 219 
fluids. The most common cooling method in the ICU was invasive cooling using an intravascular 220 
catheter (n = 218, 62%), with no significant between-group difference in the type of device used. All 221 
the patients were cooled in the ICU using an intravascular catheter or some other device.  222 
In the group given pre-ICU cold i.v. fluids, a higher number of patients received surface cooling as 223 
compared with that in the group that did not receive this treatment (50% vs. 42%, p = 0.02).  224 
Correlation of pre-ICU fluid cooling and TTT 225 
Several factors were associated with more rapid cooling in the univariate analysis (Supplementary 226 
online Table 1). Accordingly, several factors were related to the TTT in the linear regression analysis 227 
(Table 3). In the univariate analysis, the use of pre-ICU cold i.v. fluids (standardized beta coefficient: 228 
0.14, 95% CI for B 11 and 76, p = 0.01) was associated with a longer TTT. However, in a multiple 229 
linear regression model that included significant factors (e.g. ROSC delay, treatment centre, heart 230 
failure, diabetes mellitus, and BMI) associated with the TTT, the use of pre-ICU cold i.v. fluids was 231 
not associated with any change in the TTT (standardized beta coefficient: 0.06, 95% CI for B -49 and 232 
16, p = 0.32). In contrast, BMI (standardized beta coefficient: 0.29, 95% CI for B 6 and 12, p < 0.01) 233 
and previous heart failure (standardized beta coefficient: 0.13, 95% CI for B 22 and 156, p = 0.01) 234 
were associated with prolonged time from ROSC to target temperature. The linear regression model 235 
results are presented in Table 3. 236 
Patients’ temperatures in the ICU 237 
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 The mean patient temperatures for the first 24 h from ICU admission are shown in Figure 1. In a 238 
mixed linear model, the use of pre-ICU cold fluids was associated with higher mean temperatures 239 
for the first 24 h from ICU admission (p = 0.003), without any clear interaction with time. There was 240 
no difference in the proportion of patients successfully cooled or the global effectiveness of cooling 241 
between groups (Table 2).  242 
Adverse events and outcomes 243 
The occurrence of adverse events was not different in patients who did or did not receive pre-ICU 244 
fluids (Table 4). There were no significant differences in mortality after 24, 48 or 72 h (Table 4). In 245 
addition, there was no difference in the time to mortality or 180-d mortality (p = 0.8), as shown in 246 
Figure 2. Furthermore, there was no significant between-group differences in favourable 247 
neurological outcomes (CPC1 or 2) at discharge (3.9% absolute difference, p = 0.46) or 6 mo post-248 
discharge (0.6% absolute difference, p = 0.78).  249 
Discussion 250 
Main findings 251 
We studied the effects of TTM induction using pre-ICU cold i.v. fluids on the TTT and side effects of 252 
cold fluids in patients included in the randomized TTH48 trial, comparing 24 and 48 h of TTM at 253 
33°C. Patients who received pre-ICU cold fluids did not have a shorter TTT than those who did not. 254 
In addition, the body temperatures of the patients in the group that received cold fluids were higher 255 
than those of the patients who did not, despite TTM induction during the first 24 h of admission. 256 
We detected no between-group difference in side effects, such as electrolyte abnormalities or 257 
hypoxia. In accordance with the findings of previous research,19 a high BMI was associated with a 258 
prolonged TTT in the present study. The study design precludes conclusions about causality. 259 
However, taken together, the findings do not the support benefits of routine clinical use of cold 260 
fluids in TTM in the pre-ICU setting. It may well be that early TTM may be achieved using more novel 261 
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methods, such as trans-nasal-evaporative cooling, which was recently shown to be feasible in the 262 
pre-hospital setting.20 263 
 Previous animal studies on TTM induction showed that faster induction of the target temperature 264 
was beneficial.21,22 In patients, the evidence is mixed and furthermore, the efficacy of rapid cooling 265 
is difficult to ascertain in patients with severe neurological injuries given the apparent ease of 266 
cooling.3,4,12,14,23 Due to its simplicity, the use of cold fluids is appealing. However, Scales et al. 267 
reported that pre-hospital cooling initiated 5 min after ROSC did not increase the likelihood of 268 
achieving a target temperature of 32–34°C within 6 h of hospital arrival.23 On the other hand, a 269 
slightly older study by Larsson et al. pointed to the efficacy of TTM induction and maintenance with 270 
cold and ice packs in the ICU.24 In one of only a few large RCTs on TTM induction with cold fluids, 271 
the authors showed that although the use of cold fluids in the ambulance initially decreased each 272 
patient’s temperature by almost 1°C, the effect had almost disappeared 1 h later.6,25 Our study not 273 
only supports these findings but points to problems with temperature management during the 274 
following 24 h in the ICU. The results of the present study may be due to the mode of cooling, with 275 
cold fluids administered as part of a treatment protocol that favours non-invasive methods, which 276 
have been shown to be less efficient than intra-vascular cooling.26 However, as our adjusted model 277 
included the TTM treatment, the aforementioned factor cannot completely account for the lack of 278 
efficacy of pre-ICU cold i.v. fluids. Less aggressive initiation of ICU TTM by the treating team due to 279 
a false sense of security may be an alternative explanation for the TTT not decreasing in the group 280 
that received pre-ICU cold i.v. fluids. The infusion of cold fluid may also have resulted in some form 281 
of rebound hyperthermia or shivering, which would require deeper sedation. We found no 282 
difference in the initial use of sedation between the two groups. In some centres, the patients were 283 
transferred directly to the cardiac angiography suite, which may have delayed ICU admission and 284 
ICU cooling. In such cases, TTM may have been induced and maintained by the cold i.v. fluids. This 285 
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may have introduced bias, including the finding of a longer time to effective cooling in the group 286 
given pre-ICU cold i.v. fluids. However, despite a numerically longer time from ROSC to ICU 287 
admission in this group, this between-group difference in ROSC to ICU admission time was not 288 
statistically significant.  289 
We found no difference in outcomes, depending on whether the patients received or did not receive 290 
cold fluids. Nie et al. analysed five RCTs and concluded that pre-hospital TTM induced by i.v. infusion 291 
of ice-cold fluids did not improve survival to hospital discharge or neurological outcomes.14 The 292 
results of the present study are in line with those in the field. In a large RCT conducted by Kim et al., 293 
the use of pre-hospital cold fluids also failed to improve outcomes. However, the study by Kim et al. 294 
was criticized, as not all the included patients received TTM in an ICU, and the cold fluids were 295 
administered for only a few minutes using a pressure bag.27 In contrast, in the present study, all the 296 
patients were admitted to an ICU for either 24 or 48 h of TTM.  297 
Potential side effects of cold fluids may also explain the lack of benefit of cold fluids in terms of 298 
survival. However, in the present study, there were no increases in severe electrolyte disturbances, 299 
adverse haemodynamics or hypoxia. Hypoxia may develop due to fluid overload, , especially when 300 
large volumes of cold fluids are administered. Jacobshagen et al. reported that pulmonary function 301 
worsened when inducing TTM with cold fluid.28 302 
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protocol. Finally, the post hoc setting limits the generalization of the results. 312 
Conclusions 313 
In the current study, the initiation of TTM before ICU arrival using cold i.v. fluids was not associated 314 
with a decrease in the time required to reach a target temperature of < 34℃. Furthermore, patients 315 
who received cold fluids had slightly higher temperatures during the first 24 h as compared with 316 
those who did not receive cold fluids. We did not find any association between cold fluid use and 317 
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Table 1. Demographic characteristics and type of resuscitation.  433 
Variable Pre-ICU cold i.v. fluids 
given  
n = 110 
Pre-ICU cold i.v. 
fluids not given  
n = 242 
P value 
Age (y), median (IQR) 62 (54 to 69) 62 (53 to 69) 0.97 
Male sex, No. of patients (%) 86 (78) 207 (86) 0.09 
Weight (kg), median (IQR)a 87 (76 to 97) 83 (75 to 92) 0.11 
Neurological function pre-arrest, No. of patients (%) 
Normal (CPC 1)  










Medical history, No. of patients (%)    
Previous myocardial infarction 18 (16) 36 (15) 0.75 
Previous PCI or CABG 15 (14) 40 (17) 0.48 
Previous cardiac arrest 1 (1) 2 (1) 0.94 
Chronic heart failure (NYHA IV) 13 (12) 5 (2) <0.01 
Chronic obstructive pulmonary disease 7 (6) 17 (7) 0.82 
Liver cirrhosis 0 (0) 3 (1) 0.25 
Chronic renal failure with dialysis 1 (0.9) 1 (0.4) 0.57 
Diabetes mellitus 17 (16) 46 (19) 0.44 
Immunosuppression 1 (1) 2 (1) 0.94 
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Cardiac arrest location, No. of patients (%)    
Home 62 (56) 130 (54)  
0.37 Public place 38 (35) 98 (41) 
Other out-of-hospital  10 (9) 14 (6) 
Arrest witnessed, No. of patients (%)    
Bystander 95 (86) 206 (85)  
0.29 Emergency medical services 9 (8) 5 (13) 
Unwitnessed  6 (6) 23 (10) 
Type of resuscitation, No. of patients (%)    
Bystander-initiated CPR 86 (78) 207 (86) 0.09 
Shockable rhythm 94 (86) 218 (90) 0.20 
Defibrillation with AED 19 (17) 61 (25) 0.05 
Mechanical chest compression  23 (21) 67 (28) 0.16 
Intubation 109 (99) 228 (95) 0.05 
Prehospital treatment     
Epinephrine (yes), No. of patients (%) 66 (60) 155 (64) 0.47 
Amiodarone (yes), No. of patients (%) 40 (36) 105 (43) 0.21 
Time to ROSC (min), mean (SD)b 21 (11.5) 25 (20.1) 0.06 
aData missing for one patient. In some cases, the patient’s weight was estimated and not measured. bData missing for 434 
three patients. 435 
Acronym key: IQR= interquartile range, SD= standard deviation, CPC= cerebral performance category, PCI= 436 
percutaneous coronary intervention, CABG= coronary artery bypass graft, NYHA=New York Heart Association 437 
classification, CPR= cardiopulmonary resuscitation, AED= automated external defibrillator, ROSC= return of 438 
















Table 2. Cooling-related factors. 453 
Variable Pre-ICU cold i.v. fluids 
given  
n =110 
Pre-ICU cold i.v. fluids 
not given  
n = 242 
P value 
Time from ROSC to ICU admission (min) 
Median (IQR)a 
135 (86 to 191) 
 
125 (76 to 170)  0.11 
Time from ROSC to TT (min) 
Median (IQR)b 
318 (245 to 418) 281 (214 to 367) <0.01 
Amount of cold pre-ICU fluids given No. of 
patients (%)c 
   
500ml 3(4)   
1000ml 37(49)   
1500ml 8(11)   
2000ml 21(28)   
2500ml 3(4)   
3000ml 3(4)   
Successful coolingd No. of patients (%) 47 (43) 125 (52) 0.14 
Globally effective cooling, No. of patients 
(%) 
36 (33) 97 (40) 0.20 
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Pre-ICU and pre-hospital cooling, No. of 
patients (%) 
   
Pre-hospital 43 (39) 21 (9) <0.001 
In hospital (pre-ICU) 59 (54) 12 (5) 
Both 8 (7) 4 (2) 
Cooling methods in the ICU, No. of patients 
(%) 
   
Surface cooling  60 (50) 97 (42) 0.02 
Invasive cooling  67 (61) 151 (62) 0.79 
Diuresis until TT, median (IQR) 368 (180 to 593) 330 (176 to 581) 0.20 
Sedation administeredf  109 (99) 235 (97) 0.34 
Opioids administeredg  86 (78) 167 (69) 0.08 
Core temperature 
Measurement location,h No. of patients (%) 
   
Bladder 74 (90) 103 (81) 0.06 
Nasopharynx 8 (10) 25 (20) 
Temperature 72 h after time 0, mean (SD) 37.4 (0.59) 37.3 (0.85) 0.12 
aData missing for 7 patients, bdata missing for 12 patients, cdata missing for 35 patients, ddata missing for 7 patients, 454 
edata missing for 8 patients, fpropofol or midazolam, gfentanyl or remifentanil, and hdata missing for 142 patients. 455 
Acronym key: IQR= interquartile range, SD= standard deviation, ICU= intensive care unit, ROSC= return of spontaneous 456 




Table 3. Multiple linear regression of factors associated with the TTT. 459 
 460 
Acronym key: BMI= body mass index, AMI= acute myocardial ICU= intensive care unit, ROSC= return of spontaneous 461 







Independent variable Standardized beta coefficients 
in univariate analysis 




Standardized beta coefficients 
in multivariate analysis  




Weight 0.32 (2.0 and 3.8) <0.01   
BMI 0.32 (6.9 and 13) <0.01 0.29 (6 and 12) <0.01 
Previous AMI  -0.08 (-72 and 11) 0.15   
Chronic obstructive 
pulmonary disease 
0.06 (-27 and 95) 0.27   
Liver cirrhosis 0.06 (-70 and 260) 0.26   
Previous heart failure 
NYHA classification 4 
0.18 (43 and 180) <0.01 0.13 (22 and 156) 0.01 
Diabetes mellitus -0.12 (-83 and -3.7) 0.03 -0.09 (-71 and 7.5) 0.11 
ROSC delay (min) -0.12 (-1.8 and -0.13) 0.02 -0.07 (-2.0 and 0.42) 0.20 
Pre-ICU cold i.v. fluid 
treatment 
0.14 (11 and 76) 0.01 0.06 (-49 and 16) 0.32 
Cardiac arrest to ICU 
admission time (min) 
0.06 (-0.001 and 0.004) 0.24   
Hospital/site -0.11 (-1.1 and -0.02) 0.04 -0.07 (-0.94 and 0.15) 0.16 
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Table 4. Adverse events and patient outcomes. 469 
Variable Pre-ICU cold i.v. fluids 
given  
n = 110 
Pre-ICU cold i.v. 
fluids not given  
n = 242 
P value 
Seizure, No. of patients (%)    
Local 13 (12) 32 (13) 0.74 
Global  16 (15) 48 (20) 0.23 
Circulation, No. of patients (%)    
Mild 46 (42) 67 (28) 0.08 
Moderate 14 (13) 39 (16) 
Severe 6 (6) 9 (4) 
Circulatory failure 4 (4) 9 (4) 
Mild arrhythmia 25 (22) 45 (19) 0.26 
Moderate arrhythmia 16 (15) 29 (12) 
Severe arrhythmia 13 (12) 27 (11) 
Pacing 7 (6) 12 (5) 0.59 
Pulmonary, No. of patients (%)    
Hypoxia (paO2 < 8 kPa)  2 (2) 8 (3) 0.43 
Pneumonia  48 (44) 114 (47) 0.54 
Gastrointestinal, No. of patients (%)    
Mild 7 (6) 14 (6) 0.37 
Moderate 6 (6) 5 (2) 
Severe 3 (3) 9 (4) 
Renal, No. of patients (%)    
Renal replacement therapy 8 (7) 19 (8) 0.85 
Infection, No. of patients (%) 40 (36) 89 (37) 0.92 
Patient outcomes    
Died, No. of patients (%)    
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Within 24 h 1 (0.9) 1(0.4) 0.57 
Within 48 h 2 (2) 4 (2) 0.91 
Within 72 h 3 (3) 9 (4) 0.63 
In hospital 26 (24) 58 (24) 0.94 
CPC1 or 2 at ICU discharge, No. of patients (%) 62 (56) 127 (53) 0.46 
GCS score at ICU discharge,a No. of patients (%)    
3–8 8 (7) 15 (6) 0.58 
9–12 2 (2) 7 (3)  
Died within 6 mo, No. of patients (%) 34 (31) 74 (31) 0.95 
CPC1 or 2 at 6 mo, No. of patients (%) 72 (66) 160 (66) 0.78 
Length of hospital stay (d), median (IQR) 12 (7 to 20) 11 (6 to 19) 0.31 
Survivors  14(11) 13 (11) 0.93 
Non-survivors 5(7) 5(5) 0.22 
aData missing for two patients. 470 
Acronym key: IQR= interquartile range, SD= standard deviation, ICU= intensive care unit, ROSC= return of spontaneous 471 
circulation, CPC= cerebral performance category, GCS= Glasgow coma scale,  472 
 473 
Supplementary online Table 1. Factors associated with successful cooling. 474 
Variable Successful cooling 
(ROSC to TT< 294 
min) 
n = 173 
Unsuccessful cooling 
(ROSC to TT> 294 
min) 
n = 172 
P value 
Age (y), median (IQR) 61,5 (53 to 69) 62 (54 to 69) 0.89 
Male sex, No. of patients (%) 145 (83) 142 (83) 0.76 
Weighta (kg), median (IQR) 80 (75 to 90) 90 (80 to 100) <0.01 
BMI, median (IQR) 25.3 (23.8 to 27.8) 27.7 (24.8 to 30.8) <0.01 
 Neurological function pre-arrest, No. of patients (%) 
Normal (CPC1)  








Medical history, No. of patients (%)    
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Previous myocardial infarction 26 (15) 28 (16) 0.70 
Previous PCI or CABG 25 (14) 30 (17) 0.43 
Previous cardiac arrest 0 (0) 3 (2) 0.08 
Chronic heart failure (NYHA IV) 4 (2) 14 (8) 0.02 
Chronic obstructive pulmonary disease 15 (9) 8 (5) 0.14 
Liver cirrhosis 3 (2) 0 (0) 0.08 
Chronic renal failure with dialysis 1 (1) 1 (1) 0.99 
Diabetes mellitus 26 (15) 37 (22) 0.11 
Immunosuppression 1 (1) 2 (1) 0.56 
Cardiac arrest location, No. of patients (%)    
Home 93 (54) 94 (55) 0.88 
Public place 69 (40) 65 (38) 
Other out-of-hospital  11 (6) 10 (6) 
Arrest witnessed, No. of patients (%)    
Bystander 148 (86) 147 (85) 0.52 
Emergency medical services 13 (8) 9 (5) 
Unwitnessed   12 (7) 16 (9) 
Type of resuscitation, No. of patients (%)    
Bystander-initiated CPR 144 (83) 144 (84) 0.90 
Shockable rhythm 153 (88) 154 (88) 0.98 
Defibrillation with AED 33 (19) 46 (27) 0.49 
Mechanical chest compression used 48 (28) 41 (24) 0.48 
Intubation 167 (97) 164 (95) 0.58 
Pre-hospital treatment, No. of patients (%)    
Pre-ICU cold i.v. fluid bolus 48 (28) 59 (34) 0.19 
Pre-ICU cold i.v. fluid amount (ml) median (IQR) 1500 (1000 to 2000) 1000 (1000 to 2000) 0.56 
Epinephrine  110 (64) 109 (63) 0.97 
Amiodarone  73 (42) 70 (40) 0.78 
aData missing for one patient. In some cases, the patient’s weight was estimated and not measured. 475 
Acronym key: IQR= interquartile range, SD= standard deviation, CPC= cerebral performance category, PCI= 476 
percutaneous coronary intervention, CABG= coronary artery bypass graft, NYHA=New York Heart Association 477 
24 
 
classification, CPR= cardiopulmonary resuscitation, AED= automated external defibrillator, ROSC= return of 478 
spontaneous circulation, TT= target temperature 479 
 480 
Supplementary online Table 2. ICU admission outcomes. 481 
Variable Pre-ICU cold i.v. fluids 
given  
n = 110 
Pre-ICU cold i.v. fluids 
not given  
n = 242 
P value 
FiO2a, median (IQR) 60 (50 to 60) 51 (41 to 60) 0.44 
PaO2 b, median (IQR) 15 (11 to 22) 16 (12 to 23) 0.79 
Saturationc, median (IQR) 97 (92 to 99) 98 (91 to 99) 0.23 
Hyponatremia,d No. of patients (%) 2 (2) 7 (3) 0.54 
Hypernatremia,g No. of patients (%) 0 (0) 4 (2) 0.17 
Na, median (IQR) 139 (136 to 140) 138 (136 to 140) 0.32 
Hypokalaemia,e No. of patients (%) 2 (2) 11 (5) 0.20 
K, median (IQR) 4 (3 to 4) 4 (4 to 5) 0.11 
Hypochloraemia,f No. of patients (%) 25 (23) 59 (24) 0.80 
Cl, Median (IQR) 107 (104 to 110) 107 (104 to 110) 0.90 
Na, K or Cl abnormalityh No. of patients (%) 28 (25) 79 (33) 0.21 
aData missing for 8 patients, bdata missing for 2 patients, cdata missing for 36 patients, ddata missing for 7 patients, 482 
edata missing for 6 patients, fdata missing for 57 patients, gdata missing for 7 patients, and hdata missing for 52 483 
patients. 484 
Acronym key: IQR= interquartile range, FiO2= Fraction of inspired oxygen, PaO2= partial pressure of oxygen 485 
 486 
